Precision BioSciences Inc... (DTIL)
NASDAQ: DTIL
· Real-Time Price · USD
5.44
0.02 (0.37%)
At close: Oct 03, 2025, 3:59 PM
5.50
1.10%
After-hours: Oct 03, 2025, 07:35 PM EDT
0.37% (1D)
| Bid | 4.9 |
| Market Cap | 64.12M |
| Revenue (ttm) | 1.26M |
| Net Income (ttm) | -78.25M |
| EPS (ttm) | -10.05 |
| PE Ratio (ttm) | -0.54 |
| Forward PE | -2.98 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 5.7 |
| Volume | 85,312 |
| Avg. Volume (20D) | 128,739 |
| Open | 5.44 |
| Previous Close | 5.42 |
| Day's Range | 5.36 - 5.45 |
| 52-Week Range | 3.61 - 9.81 |
| Beta | 1.71 |
| Ex-Dividend Date | n/a |
About DTIL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DTIL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DTIL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsPrecision BioSciences Inc. is scheduled to release its earnings on
Nov 3, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+1.65%
DTIL stock has given up its prior gain. Precision ...
Unlock content with
Pro Subscription
2 months ago
+1.65%
Precision BioSciences shares are trading higher after the company was granted FDA orphan drug designation for PBGENE-DMD in Duchenne muscular dystrophy.
2 months ago · businesswire.com
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
